id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1657-0008,FDA,FDA-2013-E-1657,Letter from U.S. Patent and Trademark Office to Goodwin Proctor LLP,Other,Letter(s),2016-02-10T05:00:00Z,2016,2,2016-02-10T05:00:00Z,,2016-02-10T15:11:32Z,,0,0,0900006481e5cb07
FDA-2013-E-1657-0007,FDA,FDA-2013-E-1657,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2015-11-24T05:00:00Z,2015,11,2015-11-24T05:00:00Z,,2015-11-24T20:50:22Z,,0,0,0900006481d705a5
FDA-2013-E-1657-0006,FDA,FDA-2013-E-1657,"Determination of Regulatory Review Period for Purposes of Patent
Extension; JUXTAPID",Notice,Determinations,2015-04-06T04:00:00Z,2015,4,2015-04-06T04:00:00Z,2015-10-06T03:59:59Z,2015-04-06T14:12:36Z,2015-07809,0,0,0900006481a8e03a
FDA-2013-E-1657-0005,FDA,FDA-2013-E-1657,Letter from U.S. Patent and Trademark Office to Goodwin Procter LLP,Other,Letter(s),2015-02-24T05:00:00Z,2015,2,2015-02-24T05:00:00Z,,2015-02-24T16:49:45Z,,0,0,0900006481a1259e
FDA-2013-E-1657-0004,FDA,FDA-2013-E-1657,"Letter from U.S. Patent Trademark Office re JUXTAPID, 5,712,279",Other,Letter(s),2014-12-22T05:00:00Z,2014,12,2014-12-22T05:00:00Z,,2014-12-22T22:40:09Z,,0,0,090000648198d0e2
FDA-2013-E-1657-0003,FDA,FDA-2013-E-1657,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-01-31T05:00:00Z,2014,1,2014-01-31T05:00:00Z,,2014-01-31T17:08:16Z,,0,0,090000648153a1ad
FDA-2013-E-1657-0001,FDA,FDA-2013-E-1657,"Aegerion Pharmacueticals, Inc. (Goodwin Procter LLP) - Paatent Term Application",Other,Application,2013-12-19T05:00:00Z,2013,12,2013-12-19T05:00:00Z,,2013-12-19T12:47:13Z,,0,0,09000064814ca53a
FDA-2013-E-1657-0002,FDA,FDA-2013-E-1657,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-12-19T05:00:00Z,2013,12,2013-12-19T05:00:00Z,,2013-12-19T12:47:25Z,,0,0,09000064814ca53b